[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alcon Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":262},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,70,96,114,136,158,178,198,215,237],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634530","evaluation-of-tears-naturale-free-and-tears-naturale-ii-lubricant-eye-drops-100634530",false,"NCT07540884","Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops","Evaluation of the Safety and Effectiveness of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops in Subjects With Dry Eye Disease","Key Inclusion Criteria:\n\n* Able to read, understand, and sign an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC) approved informed consent form in English or French.\n* Able to attend all study visits as required as per protocol.\n* Mild to moderate dry eye disease.\n* Willing to discontinue use of all habitual artificial tear supplements and use only the study device for the entire study duration.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Any known allergic reactions to the study products or its ingredients.\n* Ocular injury to either eye in the past 3 months prior to screening.\n* Ocular surgery within the previous 6 months or ocular surgery planned during the study.\n* Use of any systemic medication known to cause dry eye for less than 1 month before the Screening\u002FBaseline visit.\n* Other protocol-defined exclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this post-market clinical follow-up (PMCF) study is to describe the effectiveness and safety of Tears Naturale® Free and Tears Naturale® II lubricant eye drops in subjects experiencing dry eye (DE) symptoms.",[26],"Dry Eye Disease",[28,29,30],"lubricating eye drops","dry eyes","artificial tears","RECRUITING","2026-06-12",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":35},"2026-06-04",{"date":39,"type":20},"2026-08",{"name":41,"class":42},"Alcon Research","INDUSTRY",6,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100630170","contralateral-claims-study-of-clareon-vivity-pro-100630170","NCT07484191","Contralateral Claims Study of Clareon Vivity Pro","Key Inclusion Criteria:\n\n* Cataracts in both eyes.\n* Preoperative corneal astigmatism of less than 1.00 diopter (D) in each eye.\n* Potential postoperative best corrected visual acuity (BCDVA) of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Desires monovision correction.\n* Predicted post-operative residual astigmatism of more than 1D in either eye.\n* Any ocular or systemic co-morbidity that, in the investigator's medical opinion, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject.\n* Other protocol-defined exclusion criteria may apply.","22 Years",{"count":52,"type":20},231,[23],"The purpose of this study is to test new versions of Clareon Vivity Pro intraocular lenses (IOLs) by comparing them to currently marketed IOLs.",[56,57],"Aphakia","Presbyopia",[59,60,61],"Cataract","Eye Surgery","Intermediate Vision","2026-06-11",{"date":34,"type":35},{"date":65,"type":35},"2026-04-28",{"date":67,"type":20},"2027-02",{"name":41,"class":42},9,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100643646","phase-3-an-investigation-of-fid-123472-ophthalmic-solution-to-vehicle-for-the-reduction-of-ocular-redness-in-adults-100643646","NCT07578363","An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults","A Multicenter, Randomized, Vehicle-Controlled Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness in Adult Subjects","Key Inclusion Criteria:\n\n* Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form.\n* Willing and able to follow all instructions and attend all study visits.\n* History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion.\n* Baseline ocular redness score greater than 1 unit on a 5-point scale in both eyes prior to randomization.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Known contraindications or sensitivity to the use of any of the study treatment(s) or their components, or any other medication required by the protocol.\n* Ocular surgical interventions within 6 months prior to Visit 1 or during the study.\n* Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study parameters.\n* Use of prohibited medications, devices, or treatments as specified in the protocol.\n* Out of range vital signs (blood pressure and\u002For pulse rate) as defined in the study protocol.\n* Abnormal intraocular pressure.\n* Other protocol-defined exclusion criteria may apply.",{"count":78,"type":20},178,[80],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.",[83],"Ocular Hyperemia",[85],"Ocular Redness","NOT_YET_RECRUITING","2026-06-08",{"date":89,"type":35},"2026-06-10",{"date":91,"type":20},"2026-09",{"date":93,"type":20},"2027-03",{"name":41,"class":42},1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":113,"locationsCount":95},"100633773","phase-3-efficacy-and-safety-of-fid-123472-ophthalmic-solution-for-ocular-redness-in-adults-100633773","NCT07531043","Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults","A Two-Arm Multicenter Clinical Trial to Investigate Efficacy and Safety of FID123472 Ophthalmic Solution Compared With Vehicle in Adult Subjects With Ocular Redness","Key Inclusion Criteria:\n\n* Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form.\n* Willing and able to follow all instructions and attend all study visits.\n* History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion.\n* Baseline investigator-assessed ocular redness score of greater than 1 on a 5-point scale in both eyes prior to randomization on Day 1 (Visit 2).\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Known contraindications or sensitivity to the use of any of the investigational product(s) or their components, or any other medication required by the protocol.\n* Ocular surgical intervention within 6 months prior to Visit 1 or during the study.\n* Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study specific parameters.\n* Use of any of the prohibited medications or devices as specified in the study protocol.\n* Out-of-range vital signs (blood pressure and\u002For pulse rate) as defined in the study protocol.\n* Abnormal intraocular pressure.\n* Other protocol-defined exclusion criteria may apply.",{"count":104,"type":20},230,[80],"The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.",[83],[85],{"date":89,"type":35},{"date":111,"type":20},"2026-10",{"date":67,"type":20},{"name":41,"class":42},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100404988","hydrus-microstent-new-enrollment-post-approval-study-100404988","NCT04553523","Hydrus® Microstent New Enrollment Post-Approval Study","The Hydrus® Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm, Clinical Trial","CONFIRM","Inclusion Criteria:\n\n* An operable, age-related cataract with best corrected visual acuity (BCVA) of 20\u002F40 or worse;\n* Diagnosis of primary open angle glaucoma treated with no more than 4 topical hypotensive medications;\n* Optic nerve appearance characteristic of glaucoma;\n* Medicated IOP less than or equal to 31 millimeters mercury (mmHg); Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Closed angle forms of glaucoma;\n* Congenital or developmental glaucoma;\n* Secondary glaucoma;\n* Use of more than 4 ocular hypotensive medications;\n* Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery;\n* Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal;\n* Other protocol-defined exclusion criteria may apply.","45 Years",{"count":124,"type":20},545,[23],"The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.",[128],"Primary Open Angle Glaucoma",{"date":89,"type":35},{"date":131,"type":35},"2020-08-25",{"date":133,"type":20},"2028-06",{"name":41,"class":42},22,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":157},"100631574","clareon-truplus-study-100631574","NCT07502456","Clareon TruPlus Study","Clareon TruPlus Single-Arm Study","Key Inclusion Criteria:\n\n* Diagnosed with bilateral cataracts and planned bilateral cataract extraction by routine phacoemulsification.\n* Potential postoperative BCDVA of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.\n* Astigmatism suitable for correction with available toric IOL models.\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and other eye conditions as specified in the protocol.\n* Moderate to severe dry eye that would affect study measurements.\n* Other protocol-specified exclusion criteria may apply.",{"count":144,"type":20},122,[23],"The purpose of this research study is to generate safety and performance data for Clareon TruPlus Monofocal Intraocular Lenses (IOLs). IOLs are medical devices that are implanted in the eye during cataract surgery to restore clear vision after the cloudy natural lens has been removed. IOLs are intended to remain in the eyes for the duration of the patient's lifetime.",[56,148],"Astigmatism",[59],"2026-06-01",{"date":152,"type":35},"2026-06-03",{"date":154,"type":35},"2026-05-26",{"date":133,"type":20},{"name":41,"class":42},5,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":167,"phases":4,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100591980","capella-scientia-development-study-100591980","NCT06987474","Capella Scientia Development Study","Capella Scientia (SCDX) Development Study","Inclusion Criteria:\n\n* Able to understand and sign an IRB\u002FIEC approved consent form;\n* Willing and able to attend study visit(s) as required by the protocol;\n* Consenting age at the jurisdiction of study site;\n* Other group-specific, protocol required inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Women of child-bearing potential;\n* Unable to fixate due to nystagmus or other eye movement abnormality (e.g., significant strabismus);\n* Unclear optical media preventing data capture from all devices in the study;\n* Contraindicated for pupil dilation (e.g., narrow angles, allergies) per investigator's clinical judgment;\n* Any ocular disease and\u002For condition that, in the investigator's clinical judgment, may put the subject at significant risk, may compromise study results, or may interfere significantly with the subject's participation in the study;\n* Other group-specific, protocol required exclusion criteria may apply.",{"count":166,"type":20},400,"OBSERVATIONAL","This study involves collecting biometry and aberration data using the next generation biometer, Unity DX.",[59],"2026-05-21",{"date":154,"type":35},{"date":173,"type":35},"2025-07-30",{"date":175,"type":20},"2027-05",{"name":41,"class":42},4,{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":177},"100604259","feasibility-study-of-an-accommodating-iol-design-100604259","NCT07147192","Feasibility Study of an Accommodating IOL Design","Key Inclusion Criteria:\n\n* Able to understand and sign an Informed Consent Form.\n* Willing and able to attend all scheduled study visits required per protocol.\n* Diagnosed with bilateral cataracts requiring removal by phacoemulsification.\n* Preoperative corneal astigmatism equal to or less than 1.50 diopter (D) in both eyes.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Women of childbearing potential who are pregnant, intend to become pregnant during the study, or are breastfeeding.\n* Taking medications that could increase risk or may affect accommodation.\n* Eye conditions as specified in the protocol, including glaucoma or ocular hypertension.\n* Medical conditions that could increase operative risk as specified in the protocol.\n* Other protocol-defined exclusion criteria may apply.",{"count":185,"type":20},85,[23],"The purpose of this clinical study is to assess safety and explore usability and effectiveness of the test product, AAL-FAIOL. This study will be conducted in Central America.",[56],[59],"2026-05-18",{"date":192,"type":35},"2026-05-19",{"date":194,"type":35},"2025-12-03",{"date":196,"type":20},"2028-01",{"name":41,"class":42},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":177},"100638560","clinical-evaluation-of-a-novel-trifocal-iol-100638560","NCT07587138","Clinical Evaluation of a Novel Trifocal IOL","Key Inclusion Criteria:\n\n* The calculated power needed for the artificial lens (IOL) must be between +15.0 and +25.0 D in each eye, designed to bring subject vision as close to \"0.0\" (neutral) as possible, meaning they will not be strongly nearsighted or farsighted after surgery.\n* Subjects must have low levels of astigmatism (misshapen cornea) in the eyes (less than 1.00 D).\n* In the doctor's opinion, the subjects have the potential to achieve good vision (0.2 logMAR, which is roughly 20\u002F32 Snellen or better) in each eye after the surgery, when wearing the best possible spectacles or contact lenses.\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Clinically significant corneal diseases which may, according to the investigator's medical opinion, adversely affect visual outcomes.\n* Any ocular or systemic health condition or medical issue that, in the investigator's medical opinion, could make the study results unreliable, prevent the person from finishing the study, or increase their safety risk.\n* People who want to have one eye set for distance vision and the other for near vision.\n* The doctor expects significant blurry vision (astigmatism) after the procedure.\n* Other protocol-specified exclusion criteria may apply.",{"count":205,"type":20},66,[23],"The purpose of this study is to understand the visual outcomes of the investigational intraocular lens (IOL) Model LPYWT0 when compared to the commercially marketed Clareon PanOptix Pro IOL Model PXYWT0.",[56,59],"2026-05-14",{"date":190,"type":35},{"date":111,"type":20},{"date":213,"type":20},"2027-07",{"name":41,"class":42},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":177},"100611293","an-evaluation-of-the-safety-and-tolerability-of-ocular-lubricants-100611293","NCT07238699","An Evaluation of the Safety and Tolerability of Ocular Lubricants","Inclusion Criteria:\n\n* Subject must be willing and able to understand and sign an ethics committee approved informed consent form.\n* Subject must be willing and able to attend all study visits as required by the protocol.\n* Subject must exhibit symptoms of dry eye at the Screening Visit.\n* Subject must currently use artificial tears.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Has any known active ocular disease and\u002For infection.\n* Has any known infection or inflammation that requires treatment or has a systemic condition that, in the opinion of the investigator, may affect a study outcome variable.\n* Any ocular injury to either eye in the 12 weeks prior to screening.\n* Current wearer of contact lenses or has a history of contact lens wear within the previous 1 month.\n* Other protocol-defined exclusion criteria may apply.",{"count":222,"type":20},148,[23],"The purpose of this study is to evaluate the safety and tolerability of two new artificial tear formulations in subjects with moderate dry eye disease.",[26],[227,228,229],"Itchy eyes","Stinging eyes","Scratchy eyes","2026-03-09",{"date":232,"type":35},"2026-03-11",{"date":234,"type":35},"2026-03-04",{"date":39,"type":20},{"name":41,"class":42},{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":167,"phases":4,"briefSummary":246,"conditions":247,"keywords":252,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":95},"100610477","surgical-procedure-efficiency-evaluation-study-100610477","NCT07228091","Surgical Procedure Efficiency Evaluation stuDy","Surgical Procedure Efficiency Evaluation stuDy (SPEED): Combination Phaco-Vitrectomy Surgeries With UNITY VCS vs. Constellation in a Real-World Operating Room Setting","Key Inclusion Criteria:\n\n* Able to understand and sign an informed consent form (ICF) that has been approved by an ethics committee.\n* Planned combined phacovitrectomy procedure at one of the selected surgical sites.\n* Planned combined phacovitrectomy procedure with 25-gauge (G) vitrectomy tools.\n\nKey Exclusion Criteria:\n\n* Unplanned\u002Femergency phacovitrectomy.\n* Pregnant.\n* Past history of phacovitrectomy. cataract, vitrectomy in the planned operative eye.\n* Other protocol-defined exclusion criteria may apply.",{"count":245,"type":20},180,"The purpose of this real-world evidence study is to compare surgical procedure times for UNITY® VCS and CONSTELLATION® Vision System.",[59,248,249,250,251],"Vitreous Hemorrhage","Retinal Detachment","Macular Pucker","Macular Holes",[253,254],"anterior segment ophthalmic surgery","posterior segment ophthalmic surgery","2026-02-12",{"date":257,"type":35},"2026-02-17",{"date":259,"type":35},"2026-02-09",{"date":39,"type":20},{"name":41,"class":42},""]